Oncosting, LLC
Baltimore, MD Doing business as Oncosting LLC
- UEI
- DJXQC89K4S79
- CAGE
- 8FZC8
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 17 S Chester St, Baltimore, MD 21231, USA
- Website
- oncosting.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| BCG overexpressing a small molecule sting agonist as a vaccine for TB - abstract tuberculosis (TB) remains the topmost… | National Institute of Allergy and Infectious Diseases | $3,239,321 | |
| Sttr phase i: recombinant BCG as a novel immunoadjuvant for viral infections -the broader impact /commercial potential… | National Science Foundation | $256,000 | |
| Sting agonist-expressing BCG for bladder cancer - abstract more than 80,000 americans are diagnosed with bladder… | National Cancer Institute | $3,640,326 |
About Oncosting, LLC
Oncosting, LLC is a corporate entity registered in SAM.gov since December 2019, operating as a for-profit limited liability company focused on innovative biotechnology research. The company specializes in developing advanced vaccine technologies, with a particular emphasis on recombinant Bacillus Calmette-Guerin (BCG) strains engineered to enhance immunological responses. While specific details about the company's full organizational structure are not provided, the federal grant award history indicates a strong research focus on developing improved vaccine candidates and immunotherapeutic approaches for challenging medical conditions.
The company has secured multiple significant federal grants from civilian agencies, primarily focusing on developing novel vaccine and immunotherapy technologies. Specifically, Oncosting, LLC has received federal grant awards from the National Institute of Allergy and Infectious Diseases (NIAID), the National Science Foundation, and the National Cancer Institute. These grants totaling over $526,000 support research on advanced BCG vaccine candidates, including OS-101 and OS-151, which are engineered to overexpress a small molecule STING agonist. The research projects span diverse medical applications, including tuberculosis prevention, viral infection immunoadjuvant development, and bladder cancer immunotherapy. Each grant focuses on creating improved vaccine platforms with enhanced efficacy, safety, and potential for broader application across multiple disease contexts, demonstrating Oncosting's commitment to innovative biomedical research and technological advancement in immunological interventions.
Quick answers
What is Oncosting, LLC's UEI?
Oncosting, LLC's Unique Entity ID (UEI) in SAM.gov is DJXQC89K4S79.
What is Oncosting, LLC's CAGE code?
Oncosting, LLC's CAGE code is 8FZC8.
What is Oncosting, LLC's primary NAICS code?
Oncosting, LLC's primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Oncosting, LLC located?
Oncosting, LLC's physical address in SAM.gov is 17 S Chester St, Baltimore, MD 21231, USA.
Is Oncosting, LLC registered in SAM.gov?
Yes. Oncosting, LLC's SAM.gov registration is active through July 2, 2027.
What is Oncosting, LLC's most recent federal award?
Oncosting, LLC's most recent federal grant award is BCG overexpressing a small molecule sting agonist as a vaccine for TB - abstract tuberculosis (TB) remains the topmost… (R44AI181290), from National Institute of Allergy and Infectious Diseases, on June 20, 2024.
On GovTribe
See Oncosting, LLC's full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors